Artivion, Inc. (AORT)
| Market Cap | 931.88M -58.7% |
| Revenue (ttm) | 481.88M +14.0% |
| Net Income | -17.64M |
| EPS | -0.37 |
| Shares Out | 48.79M |
| PE Ratio | n/a |
| Forward PE | 178.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 558,000 |
| Open | 19.62 |
| Previous Close | 19.40 |
| Day's Range | 18.95 - 19.81 |
| 52-Week Range | 18.95 - 48.25 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 38.47 (+101.41%) |
| Earnings Date | Nov 5, 2026 |
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price target is $38.47, which is an increase of 101.41% from the latest price.
News
Artivion Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Core plans for 2027 remain intact, with AMDS implant growth offsetting slower starter-set orders. NEXUS launches Jan. 1, 2027, while higher On-X capacity and Arcevo development add growth potential.
Artivion Transcript: Stifel 2026 Healthcare Conference 2026
Organic targets remain 10% revenue and 20% adjusted EBITDA growth, while PerClot exits in 2027. AMDS implants are accelerating, and NEXUS is set for a Jan. 1, 2027 launch with rollout through the year.
Artivion selloff after earnings ‘overdone,’ says Freedom Capital
Freedom Capital said Artivion (AORT) reported a “low-quality beat” on revenue in Q3 and noted that 2026 guidance ranges for revenue and EBITDA were narrowed with midpoints unchanged. The firm,…
Artivion price target lowered to $30 from $40 at Canaccord
Canaccord lowered the firm’s price target on Artivion (AORT) to $30 from $40 and keeps a Buy rating on the shares. The firm updated its model following Q3 results where…
Artivion price target lowered to $40 from $45 at Stifel
Stifel lowered the firm’s price target on Artivion (AORT) to $40 from $45 and keeps a Buy rating on the shares.
Artivion price target lowered to $42 from $48 at Citizens
Citizens analyst Daniel Stauder lowered the firm’s price target on Artivion (AORT) to $42 from $48 and keeps an Outperform rating on the shares following the Q3 earnings report. Artivion…
Artivion reports Q3 adjusted EPS 8c, consensus 7c
Reports Q3 revenue $123.8M, consensus $120.97M. “In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, prof...
Artivion narrows FY26 revenue view to $484M-$492M from $480M-$496M
FY26 consensus $490.63M. “Artivion (AORT) has narrowed its expectations for the full year 2026 and now expects revenue to be in the range of $484 to $492 million, representing growth…
Artivion Earnings Call Transcript: Q3 2026
Q3 revenue grew 9% in constant currency, while adjusted EBITDA fell 8% amid margin pressure and investment costs. FY2026 guidance narrowed to 8%-10% adjusted constant-currency growth; NEXUS is expected to launch in January 2027.
Artivion Earnings release: Q3 2026
Artivion released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Artivion Slides: Q3 2026
Artivion has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Artivion Quarterly report: Q3 2026
Artivion has published its Q3 2026 quarterly earnings report on November 5, 2026.
Artivion Reports Third Quarter 2026 Financial Results
Third Quarter & Recent Business Highlights: Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and 9%...
Artivion to Participate in Upcoming Investor Conferences
ATLANTA, Oct. 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results ...
Artivion initiated with a Buy at Jefferies
Jefferies initiated coverage of Artivion (AORT) with a Buy rating and $31 price target Artivion is a a play on aortic surgery with a “healthy cadence” of new product launches…
Artivion price target raised to $40 from $39 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Artivion (AORT) to $40 from $39 and keeps a Buy rating on the shares. The firm updated its model following…
Artivion Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is driving double-digit revenue growth with a focus on high-margin aortic products, leveraging recent PMA approvals and acquisitions to solidify its pipeline. Strong Q2 results, robust On-X valve growth, and a disciplined R&D strategy support confidence in future free cash flow and margin expansion.
Artivion price target lowered to $39.20 from $42 at Ladenburg
Ladenburg lowered the firm’s price target on Artivion (AORT) to $39.20 from $42 and keeps a Buy rating on the shares following the Q2 report.
Artivion price target raised to $39 from $36 at Canaccord
Canaccord raised the firm’s price target on Artivion (AORT) to $39 from $36 and keeps a Buy rating on the shares. The firm said Artivion had an operationally productive quarter…
Artivion reports Q2 non-GAAP EPS 13c, consensus 10c
Reports Q2 revenue $125.8M, consensus $120.01M. “In Q2, we delivered 9% constant currency revenue growth and 7% adjusted EBITDA growth, reflecting continued execution of our strategy to drive long-ter...
Artivion repeats 2026 revenue $480M-$496M, consensus $486.23M
Sees 2026 adjusted EBITDA $92M-$99M.
Artivion Earnings Call Transcript: Q2 2026
Q2 2026 saw 9% revenue and 7% adjusted EBITDA growth, driven by On-X and stent grafts, with FDA PMA approval for AMDS and the Endospan acquisition expanding the aortic arch portfolio. Guidance for 2026 is reiterated, with strong outlook for AMDS and NEXUS launches.
Artivion Earnings release: Q2 2026
Artivion released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Artivion Slides: Q2 2026
Artivion has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.